Aura Biosciences (AURA) Corporate presentation summary

Strategic vision and market opportunity

• Aims to transform ocular cancer care with targeted therapies, focusing on early choroidal melanoma and other ocular cancers.

• Positioned to become a global leader in ocular oncology, targeting a multi-billion-dollar addressable market with high unmet need.

• Potential to deliver the first curative, vision-preserving therapy for early choroidal melanoma, with expansion opportunities into other ocular cancers.

• Focused commercial strategy leverages synergies across indications and a concentrated specialist call point.

• Expected cash runway extends into the first half of 2029, supporting long-term value creation.

Clinical pipeline and product profile

• Lead candidate bel-sar is a novel, targeted VLP-drug conjugate with dual mechanisms: targeted cytotoxicity and immune activation.

• Clinical pipeline includes programs for early choroidal melanoma (phase 3), metastases to the choroid (phase 2), and ocular surface cancers (preclinical).

• Bel-sar is administered via suprachoroidal injection as an in-office procedure, aiming for local tumor control and vision preservation.

• Phase 3 COMPASS trial is fully enrolled, with topline data expected in the second half of 2027.

Clinical data and efficacy

• Phase 2 trial in early choroidal melanoma showed an 80% tumor control rate at 12 months in phase 3-eligible patients using the therapeutic regimen.

• 90% of these patients preserved visual acuity, supporting bel-sar as a potential frontline therapy.

• Significant reduction in tumor growth rate post-treatment, with robust statistical significance (P < 0.0001).

• Phase 3 trial design is highly powered for success, leveraging phase 2 data and robust statistical modeling.